Parkinson's Disease Treatment Market

Market Overview:

The global parkinson's disease treatment market size reached US$ 5.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 8.2 Billion by 2032, exhibiting a growth rate (CAGR) of 5.42% during 2024-2032.

Parkinson’s disease refers to a progressive neurological disorder caused by the degeneration of motor neurons in the brain. It is characterized by rigidity, tremors, difficulty in walking, motor impairment, depression and dementia. Some of the common treatment options for this disorder include medications, supportive therapies and surgical procedures, such as deep brain stimulation. Medications include carbidopa-levodopa medicines, dopamine agonists, monoamine oxidase B (MAO B) inhibitors, catechol O-methyltransferase (COMT) inhibitors and anticholinergics. These treatment methods are highly effective in managing the symptoms of Parkinson’s disease and providing comfort to the patient in case of a seizure.

Global Parkinson's Disease Treatment Market Trends and Drivers:

The increasing prevalence of Parkinson’s disease, and the rising geriatric population across the globe, which is more susceptible to neurodegenerative ailments, represent as the key factors driving the growth of the market. Furthermore, the increasing awareness among the masses regarding the available treatment alternatives is also stimulating the market growth. In line with this, COMT inhibitors are gaining immense traction among healthcare providers and patients. They are administered along with co-therapeutic agents and carbidopa-levodopa therapy for maximum efficiency. Additionally, various innovations in the disease treatment methods, such as the development of neurostimulation tools, gene therapy and neural transplantation procedures, are acting as other growth-inducing factors. These procedures aid in prolonged action of unremitting dopaminergic stimulation medicines and facilitate slowing down the disease progression, which, in turn, is creating a positive outlook for the market. Other factors, including significant improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global parkinson's disease treatment market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on drug class, route of administration and distribution channel.

Breakup by Drug Class:

• Carbidopa/Levodopa
• Dopamine Receptor Agonists
• MAO Inhibitors
• COMT Inhibitors
• Anticholinergics
• Others
   

Breakup by Route of Administration:

• Oral
• Transdermal
• Subcutaneous
• Intestinal Infusion
• Others
   

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Acadia Pharmaceuticals Inc., Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG), F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, H. Lundbeck A/S, Merck & Co. Inc., Mylan N.V., Novartis AG, Orion Corporation, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries and Wockhardt Ltd.

Report Coverage:

Key Questions Answered in This Report:

• How has the global parkinson’s disease treatment market performed so far and how will it perform in the coming years?
• What are the key regional markets?
• What has been the impact of COVID-19 on the global parkinson’s disease treatment market?
• What is the breakup of the market based on the drug class?
• What is the breakup of the market based on the route of administration?
• What is the breakup of the market based on the distribution channel?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global parkinson’s disease treatment market and who are the key players?
• What is the degree of competition in the industry?